IDev Technologies, Inc. Gains CE Mark Approval for New Nitinol Stent in Peripheral Vascular Disease
HOUSTON, May 3 /PRNewswire/ -- IDev Technologies, Inc., an emerging leader in the development and marketing of minimally invasive stent systems for the treatment of peripheral vascular and non-vascular diseases, today announces CE Mark approval for use of its stent in Europe. Specifically, the CE Mark approval is in respect to the design, development and manufacture of devices for removal of inadvertently dislodged or misplaced objects from peripheral body vasculature, for palliative treatment of Biliary strictures produced by malignant neoplasms and for use in peripheral vasculature for failed PTA. Thomas M. Tully, Chairman and CEO commented, "European approval for the IDev Technologies, Inc. stent is the first critical step toward the commercialization of this novel technology worldwide. The company is initially preparing a limited distribution strategy to elite interventional centers throughout Europe. These elite centers will be the first to offer the innovative IDev Technologies, Inc. stent to over 2.5 million patients who suffer from Critical Limb Ischemia in the developed world." About IDev Technologies, Inc. IDev Technologies, Inc. ("IDEV") is an Innovator and Developer of next generation minimally invasive medical devices for the treatment of peripheral vascular disease (PVD). PVD is currently treated by interventional radiologists, vascular surgeons, and cardiologists. The Company has recently received a CE Mark approval for use of the stent in peripheral vascular and non-vascular applications and is preparing to launch the product in Europe shortly. The IDev Technologies, Inc. stent is a unique device that is a self- expandable nitinol stent with significant radial force that is resistant to kinking, crushing and fracture potential. Additionally, the unique delivery system allows for precise placement and repositionability prior to deployment. These features represent a significant advance over existing stent technologies for peripheral vascular applications.
SOURCE IDev Technologies, Inc.
More by this Source
IDEV gibt Ergebnisse von Studie zur Revaskularisation mit Supera an echten Patienten (RESTORE) bekannt - Studie demonstriert positive klinische Ergebnisse bei schwerkranken Patienten mit langen Läsionen
Feb 01, 2013, 09:16 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.